MAXIMAL BRONCHODILATION WITH STARTING THERAPY OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE: AN INFLUENCE ON THE COURSE OF THE DISEASE
https://doi.org/10.18093/0869-0189-2016-26-5-604-609
Abstract
Progressive airflow limitation is a principal sign of chronic obstructive pulmonary disease (COPD) which leads to pulmonary hyperinflation, progressive exertional breathlessness, reducing physical activity in daily life, deconditioning and significant decrease in quality of life. This phenomenon is noted in early stage of COPD. The earliest disruption of this 'vicious circle' is thought to result in better clinical outcome. Current combined bronchodilator therapy, such as a fixed combination of tiotropium/olodaterol, can significantly improve clinical status, dyspnea, physical limitation, deconditioning and quality of life of the patients due to improvement in bronchial obstruction and pulmonary hyperinflation. Therefore, the most promising approach today and in the nearest future is to start the optimal combined dual bronchodilator therapy at earlier stage of the disease.
About the Authors
S. N. Avdeev
Federal Pulmonology Research Institute, Federal Medical and Biological Agency of Russia: 32, build. 4, 11th Parkovaya str., Moscow, 105077, Russia
Russian Federation
Russian Federation
Z. R. Aisanov
Federal Pulmonology Research Institute, Federal Medical and Biological Agency of Russia: 32, build. 4, 11th Parkovaya str., Moscow, 105077, Russia
Russian Federation
Russian Federation
References
1. Global Initiative for Chronic Obstructive Lung Diseases (GOLD). Global strategy for diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO workshop report. Updated 2017. GOLD website (www.goldcopd.com).
2. Chuchalin A.G., Aysanov Z.R., Avdeev S.N., et al. Federal Clinical Guidelines on Diagnosis and Management of Chronic Obstructive Pulmonary Disease. Pul'monologiya. 2014; 3: 15–54 (in Russian).
3. Anthonisen N.R., Wright E.C., the IPPB Trial Group. Bronchodilator response in chronic obstructive pulmonary disease. Am. Rev. Respir. Dis. 1986; 133: 814–819.
4. Hanania N.A., Sharafkhaneh A., Celli B. et al. Acute bronchodilator responsiveness and health outcomes in COPD patients in the UPLIFT trial. Respir. Res. 2011, 12: 6.
5. Avdeev S.N. A role of pulmonary hyperinflation for pathogenesis of COPD. An efficacy of basic therapy for reduction of pulmonary hyperinflation. Pul'monologiya. 2004; 6: 101–110 (in Russian).
6. Rossi A., Aisanov Z., Avdeev S. et al. Mechanisms, assessment and therapeutic implications of lung hyperinflation in COPD. Respir. Med. 2015; 109: 785–802.
7. O’Donnell D.E., Lam M., Webb K.A. Measurement of symptoms, lung hyperinflation, and endurance during exercise in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med.1998; 158: 1557–1565.
8. Casarosa P., Bouyssou T., Germeyer S.et al. Preclinical evaluation of long-acting muscarinic antagonists: comparison of tiotropium and investigational drugs. J. Pharmacol. Exp. Ther. 2009; 330: 660–668.
9. Rennard S., Bantje T., Centanni S. et al. A dose-ranging study of indacaterol in obstructive airways disease, with a tiotropium comparison. Respir. Med. 2008; 102: 1033–1044.
10. Singh D., Magnussen H., Kirsten A. et al. A randomised, placebo- and active-controlled dose-finding study of aclidinium bromide administered twice a day in COPD patients. Pulm. Pharmacol. Ther. 2012; 25: 248–253.
11. Cazzola M., Page C.P., Calzetta L., Matera M.G. Pharmacology and therapeutics of bronchodilators. Pharmacol. Rev. 2012; 64: 450–504.
12. Calverley P.M., Burge P.S., Spencer S. et al. Bronchodilator reversibility testing in chronic obstructive pulmonary disease. Thorax. 2003; 58: 659–664.
13. Cazzola M., Segreti A., Matera M.G. New developments in the combination treatment of COPD: focus on umeclidinium/vilanterol. Drug Des. Devel. Ther. 2013; 7: 1201–1208.
14. Beeh K-M, Westerman J, Kirsten A-M, et al. The 24-h lung function profile of once-daily tiotropium and olodaterol fixed-dose combination in chronic obstructive pulmonary disease. Pulm. Pharmacol. Ther. 2015; 32: 53-59.
15. Buhl R, Maltais F, Abrahams R, et al. Tiotropium and olodaterol fixed-dose combination versus mono-components in COPD (GOLD 2-4). Eur. Respir. J. 2015; 45: 969-979.
16. Ferguson G.T., Flezar M., Korn S. et al. Efficacy of tiotropium+olodaterol in patients with chronic obstructive pulmonary disease by initial disease severity and treatment intensity: a post hoc analysis. Adv. Ther. 2015; 32: 523–536.
17. Singh D., Ferguson G.T., Bolitschek J. et al. Tiotropium + olodaterol shows clinically meaningful improvements in quality of life. Respir. Med. 2015; 109: 1312–1319.
18. Profita M., Bonanno A., Montalbano A.M. et al. Beta2-long-acting and anticholinergic drugs control TGF β1-mediated neutrophilic inflammation in COPD. Biochim. Biophys. Acta. 2012; 1822: 1079–1089.
19. Price D., Freeman D., Cleland J. et al. Earlier diagnosis and earlier treatment of COPD in primary care. Prim. Care Respir. J. 2011; 20: 15–22.
20. Lee J.Y., Rhee C.K., Jung K.S., Yoo K.H. Strategies for management of the early chronic obstructive lung disease. Tuberc. Respir. Dis. 2016; 79: 121–126.
21. Avdeev S.N. A choice of optimal therapy for early-stage chronic obstructive pulmonary disease. Spravochnik poliklinicheskogo vracha. 2009; 11: 27–31 (in Russian).
22. Rennard S., Decramer M., Calverley P.M. et al. Impact of COPD in North America and Europe in 2000: subjects’ perspective of Confronting COPD International Survey. Eur. Respir. J. 2002; 20: 799–805.
23. Pinto-Plata V.M., Celli-Cruz R.A., Vassaux C. et al. Differences in cardiopulmonary exercise test results by American Thoracic Society / European Respiratory Society – Global initiative for chronic obstructive lung disease stage categories and gender. Chest. 2007; 132; 1204–1211.
24. Watz H., Waschki B., Meyer T., Magnussen H. Physical activity in patients with COPD. Eur. Respir. J. 2009; 33: 262–272.
25. Hole D.J., Watt G.C., Davey-Smith G. et al. Impaired lung function and mortality risk in men and women: findings from the Renfrew and Paisley prospective population study. Br. Med. J. 1996; 313: 711–715.
26. Schunemann H.J., Dorn J., Grant B.J. et al. Pulmonary function is a long-term predictor of mortality in the general population: 29-year follow-up of the Buffalo Health Study. Chest. 2000; 118: 656–664.
27. Tantucci C., Modina D. Lung function decline in COPD. Int. J. COPD. 2012; 7: 95–99.
28. O'Donnell D.E., Laveneziana P., Ora J. et al. Evaluation of acute bronchodilator reversibility in patients with symptoms of GOLD stage I COPD. Thorax. 2009; 64: 216–223.
29. Johansson G., Lindberg A., Romberg K. et al. Bronchodilator efficacy of tiotropium in patients with mild to moderate COPD. Prim. Care Respir. J. 2008; 17: 169–175.
30. Beeh K.M., Beier J., Buhl R. et al. Efficacy of tiotropium bromide (Spiriva) in patients with chronic-obstructive pulmonary disease (COPD) of different severities. Pneumologie. 2006; 60: 341–346 (in German).
Review
For citations:
Avdeev S.N., Aisanov Z.R. MAXIMAL BRONCHODILATION WITH STARTING THERAPY OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE: AN INFLUENCE ON THE COURSE OF THE DISEASE. PULMONOLOGIYA. 2016;26(5):604-609. (In Russ.) https://doi.org/10.18093/0869-0189-2016-26-5-604-609
Views:
9392
Email this article 